Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market

MELBOURNE, Australia, May 17, 2023 -- Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced... | May 17, 2023

Related Keywords

Australia ,Melbourne ,Victoria ,Hershel Berry ,Rudi Michelson ,Elemer Piros ,Megan Baldwin ,Timothye Morris ,Opthea Limited ,Investment In Biotechnology Companies ,Company Media Enquiries ,Blueprint Life Science Group ,Nasdaq ,Monsoon Communications ,Globenewswire Inc ,Senior Biotechnlogy Analyst ,Managing Director ,Biotechnology Companies ,Media Enquiries ,Opthea Limited Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Opthea ,Imited ,Linical ,Stage ,Iopharmaceutical ,Company ,Developing ,Novel ,Therapies ,O ,Treat ,Ighly ,Prevalent ,End ,Progressive ,Etinal Opt Au000000opt2 ,